Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. (2017)
Attributed to:
Maximising patient benefit: Leeds’ Interdisciplinary approach to translation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/annrheumdis-2017-211191
PubMed Identifier: 28684557
Publication URI: http://europepmc.org/abstract/MED/28684557
Type: Journal Article/Review
Volume: 76
Parent Publication: Annals of the rheumatic diseases
Issue: 11
ISSN: 0003-4967